


Research Article

Urinary exosomal long noncoding RNAs serve as biomarkers for early detection of non-small cell lung cancer

Quan Lin¹, Danli Xie^{2,3,4}, Liangliang Pan^{2,3,4}, Yongliang Lou^{2,3,4} and  Mengru Shi^{2,3,4}

¹The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325035, China; ²Zhejiang Provincial Key Laboratory of Medical Genetics, Wenzhou, Zhejiang 325035, China; ³Key Laboratory of Laboratory Medicine, Ministry of Education, Wenzhou, Zhejiang 325035, China; ⁴School of Laboratory Medicine and Life Science, Wenzhou Medical University, Wenzhou, Zhejiang 325035, China

Correspondence: Mengru Shi (shimr@wmu.edu.cn) or Yongliang Lou (lyl@wmu.edu.cn)



Objective: Increasing the efficiency of early diagnosis using noninvasive biomarkers is crucial for enhancing the survival rate of lung cancer patients. We explore the differential expression of non-small cell lung cancer (NSCLC)-related long noncoding RNAs (lncRNAs) in urinary exosomes in NSCLC patients and normal controls to diagnose lung cancer.

Methods: A differential expression analysis between NSCLC patients and healthy controls was performed using microarrays. Gene ontology (GO) term and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses were used to predict potential functions of lncRNAs in NSCLC. quantitative real-time PCR (QT-PCR) was used to verify microarray results.

Results: A total of 640 lncRNAs (70 up- and 570 down-regulated) were differentially expressed in NSCLC patients in comparison to healthy controls. Six lncRNAs were detected by QT-PCR. GO term and KEGG pathway analyses showed that differential lncRNAs were enriched in cellular component organization or biogenesis, as well as other biological processes and signaling pathways, such as the PI3K-AKT, FOXO, p53, and fatty acid biosynthesis.

Conclusions: The differential lncRNAs in urinary exosomes are potential diagnostic biomarkers of NSCLC. The lncRNAs enriched in specific pathways may be associated with tumor cell proliferation, tumor cell apoptosis, and the cell cycle involved in the pathogenesis of NSCLC.

Introduction

Lung cancer is one of the three most commonly occurring malignancies on a global scale. Non-small cell lung cancer (NSCLC) accounts for 85% of lung cancer cases [1,2]. Despite considerable advances in the early diagnosis and treatment of early-stage lung cancer, the 5-year survival rate of NSCLC patients remains low, and early diagnosis of NSCLC is still a major challenge [3,4]. Therefore, the exploration of potential molecular targets for early detection or intervention/treatment of lung cancer is urgently needed to reduce lung cancer mortality [5,6].

Exosomes are microvesicles with diameters of 30–100 nm secreted by a large variety of cells from various biofluids that carry a repertoire of functional biomolecules, including genomic DNA, RNA, microRNA, long noncoding RNAs (lncRNAs), and protein [7,8]. Exosomes serve as potential biomarkers for early cancer detection [9]. The lung cancer-derived exosome represents the cell of origin in numerous aspects [4,10]. Hence, it must be intensively studied to better understand cell–cell communication and cancer proliferation.

Received: 22 April 2021
Revised: 24 September 2021
Accepted: 27 September 2021

Accepted Manuscript online:
28 September 2021
Version of Record published:
12 October 2021

Table 1 Clinical characteristics of NSCLC patients and healthy controls

Study groups	Number of samples	Parameters	
NSCLC patients	20	Gender	n (%)
		Male	10 (50)
		Female	10 (50)
		Age (years) mean \pm SD	64.60 \pm 7.8
		Pathological type	n (%)
		Squamous carcinoma	6 (30)
		Adenocarcinoma	14 (60)
		Clinical stage	n (%)
		I + II stage	7 (35)
		III + IV stage	13 (65)
Healthy controls	20	Gender	n (%)
		Male	10 (50)
		Female	10 (50)
		Age (years) mean \pm SD	52.6 \pm 11.09

LncRNAs are a group of noncoding RNAs with more than 200-nucleotide length [11,12]. Recently, numerous experimental and clinical evidence have shown that lncRNAs are involved in epigenetic regulation, remodeling of chromosomes, transcription, and post-transcriptional regulation and play important roles in tumorigenesis and tumor progression [13,14]. The reduction in several lncRNAs has been reported in various tumors, such as colorectal carcinoma, osteosarcoma, hepatocellular carcinoma, gastric cancer, bladder cancer, and lung cancer [15–19]. The correlation between lncRNAs and the pathogenesis of NSCLC has received significant attention [20]. To date, there have also been studies focusing on the analysis of lncRNAs in exosomes. Some studies have demonstrated that numerous lncRNAs in exosomes such as GAS5-AS1, lncRNA BX357664, HOTTIP, and MALAT1 have their potential role in the diagnosis, prognosis, and treatment of lung cancer patients [21–24]. In the study of Zhang et al. [24], exosomal *MALAT-1* was highly expressed in NSCLC patients. Exosomal lncRNA *MALAT-1* was demonstrated to be associated with the growth and proliferation of tumor cells. Dong et al. found that exosomal lncRNAGAS5 was down-regulated in NSCLC patients [25]. However, the functions and mechanisms of lncRNAs in NSCLC have not been fully understood. In the present study, we compared several lncRNAs in the urinary exosome samples between NSCLC patients and healthy controls using microarrays to explore the differential expression of exosome lncRNAs and miRNAs. The results revealed the dysregulation of lncRNAs and miRNAs in exosomes from urine samples. We used the Gene ontology (GO) and the Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses to evaluate the potential signaling pathway of differential expression lncRNAs and we then constructed the interaction network of lncRNAs–mRNA. Our data suggest that the specific lncRNAs and miRNAs in urinary exosomes can serve as noninvasive biomarkers for the diagnosis of early-stage NSCLC.

Materials and methods

Patients and samples

Twenty NSCLC patients (age [mean \pm SD] = 64.60 \pm 7.8 years) from the Department of Respiratory Medicine of the First Affiliated Hospital of Wenzhou Medical University were enrolled in the present study. All patients had confirmed pathological diagnosis according to the 2017 lung cancer staging system of the AJCC Cancer Staging Manual 8e [26]. The 20 control subjects were healthy volunteers. The clinical information on patients and controls is listed in Table 1.

Patients with the following conditions were excluded: (1) suffering from other rheumatological diseases; (2) having concomitant complications of severe heart, kidney, or liver disease; (3) having received prior therapy for NSCLC, including chemotherapy, chemoradiotherapy, biological/targeted therapy, or any investigational drug. All analyses were performed following relevant ethical guidelines and regulations. The research was approved by the Ethics Committee of The First Affiliated Hospital of Wenzhou Medical University. And the research has been carried out in accordance with the World Medical Association Declaration of Helsinki*. All study participants signed informed consent.

Urine sample collection

A total of 200 ml first-morning urine samples was collected from each participant and mixed with 16.8 ml protease and phosphatase inhibitors (1.67 ml of 100 mmol/l Na₂S₂O₈, 2.5 ml of 10 mmol/l PMSF, 50 μ l of 1 mmol/l Leupeptin for

every 50-ml urine) immediately after collection. All samples were centrifuged at $1000\times g$ for 10 min at 4°C to remove cell pellets and then stored at -80°C until further use.

Urine exosome isolation

The thawed urine samples were centrifuged at $17000\times g$ for 20 min at 4°C to remove whole cells, large membrane fragments, and other debris. The supernatants were ultracentrifuged at $200000\times g$, for 1 h at 4°C in the Beckman Qtiima100 ultracentrifuge (Beckman, U.S.A.) to obtain sediments [27,28]. The sediments were resuspended in 0.01 mol/l of PBS solution.

Negative staining by transmission electron microscopy

A total of 20 μl of exosome suspension was loaded on a 100 mesh sample-loaded copper mesh and left at room temperature for 1 min. Excess liquid was blotted with filter paper from the other side of the grid. Subsequently, the exosome sample was stained with 3% phosphotungstic acid for ~ 10 min after air-drying. Samples were observed under transmission electron microscopy (TEM H-7500, Hitachi, Japan).

Nanoparticle tracking analysis

The exosome hydrodynamic size and number were obtained by nanoparticle tracking analysis (NTA), performed by Nano Sight NS300 (Malvern Panalytical, Ltd.) equipped with rapid video capturing following the manufacturer's instructions [29,30].

Western blot

Total urinary exosome proteins were extracted using the RIPA lysis buffer (50 mmol/l Tris-HCl (pH 7.4), 150 mmol/l NaCl, 1% NP-40, 0.1% SDS, 1 mmol/l PMSF). Protein concentrations were measured by the BCA Protein Assay Kit (ab102536, Abcam). A Western blot was performed using 12% polyacrylamide/SDS gels (SDS/PAGE) in a Mini Trans-Blot module (Bio-Rad, U.S.A.) and transferred on to polyvinylidene fluoride (PVDF, GE) membranes. After blocking, the membranes were probed overnight with primary antibodies against CD63 (ab134045, Abcam, 1:1000), CD9 (ab263019, Abcam, 1:1000), and TSG101 (sc-7964, Santa Cruz, 1:1000). The membranes were washed three times with TBST the following day and incubated with HRP-conjugated anti-mouse IgG or HRP-conjugated anti-rabbit IgG (1:1500, Santa Cruz) as the secondary antibody at room temperature for 1 h. The signals were visualized with the enhanced chemiluminescence (ECL) kit (Thermo Scientific, U.S.A.) using the ChemiDoc MP Imaging System (Bio-Rad, U.S.A.) according to the manufacturer's instructions.

RNA extraction of exosome

The total RNA of exosomes was extracted using the TRIzol reagent (Invitrogen, Carlsbad, CA, U.S.A.), and the concentration and quality of RNA were determined by quantification on the Nanodrop 2000 (Thermo Scientific, U.S.A.). The RNA integrity was detected by Agilent Bioanalyzer 2100 (Agilent Technologies, U.S.A.). Total RNA was purified using a QIAGEN RNeasy Mini Kit (QIAGEN).

Library construction and RNA sequencing using microarray hybridization

Total purified RNA from each sample was reverse transcribed into first-strand cDNA using an AffinityScript-RT kit and promoter primer (Agilent Technologies, U.S.A.). Subsequently, second-strand cDNA was generated using an antisense promoter (Agilent Technologies, U.S.A.). The double-stranded cDNA was used as a template for amplification with T7 RNA polymerase to create antisense cRNA. The cRNA was labeled with Cyanine-3 (Cy3) CTP, and then purified by a QIAGEN RNeasy mini kit (QIAGEN). Labeled cRNA was then fragmented and hybridized on to the LC Biotech human lncRNA microarray (Agilent). The microarrays were incubated for 17 h at 65°C in an Agilent hybridization oven. Following washing, the microarrays were scanned using the Agilent Scanner G5761A (Agilent Technologies, Inc.).

Differential expression analysis of lncRNAs

The image data were processed using the Feature Extraction version 12.0.3.1 (Agilent Technologies). Raw data were normalized by the Quantile algorithm in Genespring (version 14.8, Agilent Technologies) software. The standardized data were filtered, and at least one set of 100% probes labeled 'Detected' from each set of samples was used for comparison was stored for subsequent analysis. Differential gene expression of the lncRNAs was considered significant

Table 2 Nucleotide sequence of primers used for verification of the differentially expressed lncRNAs in NSCLC patients

Gene name	Forward primer	Reverse primer
lnc-FRAT1-5	ACTGCTGCGAGGAGGAAAT	GCCCTGGATGTGTGCTTTTC
lnc-SRY-11	TGACTTCTCAGGGCTGCAAG	TGAGGGTTCCAAGTTCACGG
lnc-RNASE13-1	TCAGCAGGGTTGGGAATGTC	CCAGCACCATCCCCCTTCTTT
lnc-RP11-80A15.1.1-2	GCCAAGCCTGCTATCTCCTA	GGTGTCAATGTGGCTTTGGG
lnc-ARL6IP6-4	TCAACCTTGACTTCAGGGCC	AGACTTAACAATTGGCGCGC
lnc-DGKQ-1	GGCTTTACCAGGCCTTCTGT	TTCCTACACATGGTGCCAC
U6	GCGCGTCGTGAAGCGTTC	GTGCAGGGTCCGAGGT

for $P \leq 0.05$ obtained by the Student's t test between groups. The clinical information on patients and controls is listed in Supplementary Table S1.

Cluster analysis of differential lncRNA expression

The hierarchical cluster analysis of differentially expressed lncRNAs was performed using CLUSTER3.0, and the following volcano plot and heatmap analysis were performed.

Validation by quantitative real-time PCR

Reverse transcription and quantitative real-time PCR (QT-PCR) were performed to confirm the difference in the expression of the six selected lncRNAs between NSCLC patients and the control group. **ChamQ™ Universal SYBR® qPCR Master Mix (Vazyme, China)** was used to perform QT-PCR on the CFX96 system (Bio-Rad Laboratories, Inc., Hercules, CA, U.S.A.). After normalization to U6, the relative expression level of lncRNA was calculated by the $2^{-\Delta\Delta C_T}$ method. The primer sequences are listed in Table 2.

Target gene prediction and functional analysis

lncRNA regulates the neighboring genes' expression, which can be predicted based on the position within a range of 100 kb of its target gene of lncRNA and mRNA. To explore the function of lncRNAs, we first predicted the *cis* and *trans* target genes of lncRNAs.

Differentially expressed lncRNAs were then further analyzed with GO enrichment and KEGG pathway database to identify the involved enriched pathways of all differentially expressed genes. In GO enrichment analysis, there are three structured relationships of defined terms that describe gene product attributes, namely, the biological process, molecular function, and cellular component. The KEGG pathway analysis was carried out to reveal potential signaling clusters covering the differentially expressed genes. $P < 0.05$ was considered statistically significant.

Statistical analysis

All statistical analyses were performed using the GraphPad Prism 5.0 (GraphPad Software, La Jolla, CA, U.S.A.) and SPSS 26.0 software (SPSS, Chicago, IL, U.S.A.). Differences of each exosomal lncRNA between NSCLC patients and control samples were performed using the t test for paired data. $P \leq 0.05$ was considered statistically significant.

Results

Isolation and verification of urinary exosomes

We used ultracentrifugation to isolate urinary exosomes from NSCLC patients and healthy controls. Qualitative negative staining electron microscopy was used to verify whether the sediments were exosomes. In TEM analysis, isolated urinary exosome vesicles appeared as flattened spheres with diameters ranging from approximately 30 to 150 nm (Figure 1A).

Then, the Western blot was used to detect the levels of CD63, CD9, and Tsg101 proteins, which are commonly enriched and located in exosome membranes. As shown in Figure 1B, the three proteins could be detected in urinary exosomes from NSCLC patients and healthy controls. The full, uncropped, and unedited versions of Western blots are shown in Supplementary Figure S1. The result of NTA demonstrated that most of the exosomes had a diameter of approximately 143 ± 2.9 nm (Figure 1C).




Figure 1. Characterization of urinary exosomes in NSCLC

(A) Urinary exosomes visualized by transmission electron microscopy. Exosomes are indicated by red arrows. Scale bar = 100 nm. (B) Western blotting results for exosome-enriched proteins CD63, CD9, and Tsg101. (C) NTA result of exosomes.

Differential expression analysis of lncRNAs

Differential expression analysis between NSCLC patients ($n=3$) and healthy controls ($n=3$) was performed using microarrays. The results showed that the expression of 640 lncRNAs was significantly different between the two groups (Supplementary Table S2). Among them, 70 lncRNAs were up-regulated, while 570 were down-regulated ($P<0.05$). The top ten up- and down-regulated differentially expressed lncRNAs are listed in Table 3. The lncRNAs expression profile was established and clustered using hierarchical cluster analysis. The heatmap and volcano plots are shown in Figure 2A,B.

Verification of differentially expressed lncRNAs in NSCLC patients

Three up-regulated and three down-regulated lncRNAs were chosen to be validated by QT-PCR. The data shown in Figure 3 verified that the expression levels of lnc-FRAT1-5, lnc-SRY-11, and lnc-RNASE13-1 in NSCLC patients ($n=20$) were significantly higher than those in healthy individuals ($n=20$) ($P<0.001$, Figure 3A–C). In turn, the expression levels of lnc-RP11-80A15.1.1-2, lnc-ARL6IP6-4, and lnc-DGKQ-1 were significantly down-regulated ($P<0.001$, Figure 3D–F). A melting curve of one of the primers is shown in Supplementary Figure S2.

lncRNAs functional analysis by GO analysis and KEGG pathway

GO analysis (biological processes, molecular functions, and cellular components) was used to analyze the differential expression of urinary lncRNAs between NSCLC patients and healthy controls (Figure 4A). The classification revealed the top 20 GO terms (Figure 4B). The KEGG pathway analysis identified associations with 20 pathways ($P<0.05$), including the PI3K-AKT signaling pathway, FOXO signaling pathway, fatty acid biosynthesis, and p53 signaling pathway (Figure 4C).

We used the TargetScan software for miRNA target prediction to theoretically predict interactions between lncRNAs and the *cis* and *trans* target miRNAs within the 100-kb window of each lncRNA ($P\leq 0.05$). The correlation between lncRNAs and mRNAs was expressed as an absolute value of the Pearson correlation ≥ 0.7 and ≤ -0.7 . The data displayed each lncRNA and its potential complementary binding mRNAs (Figure 4D). A total of 98 lncRNAs

Table 3 Top ten up-regulated and ten down-regulated lncRNAs of urinary exosomes in NSCLC patients and controls

Probe name	Log2 fold change	Regulation	P _{val}	Gene name	Chr
CUST_13585.PI437845420	0.64	Up	0.00	lnc-FRAT1-5	chr10
CUST_10296.PI437845420	0.59	Up	0.01	lnc-SRY-11	chrY
CUST_3081.PI437859739	0.48	Up	0.01	lnc-RNASE13-1	chr14
CUST_20092.PI437845250111	0.43	Up	0.01	CECR5-AS1	chr22
CUST_6692.PI437845420	0.20	Up	0.01	lnc-ANKIB1-2	chr7
CUST_9192.PI437845420	0.20	Up	0.00	lnc-GARNL3-2	chr9
CUST_7029.PI437859739	0.17	Up	0.01	lnc-EPHX3-3	chr19
CUST_13340.PI437845420	0.13	Up	0.00	lnc-KCNMB2-11	chr3
CUST_4271.PI437845420	0.12	Up	0.00	lnc-ITK-2	chr5
A_22.P00019021	0.09	Up	0.01	lnc-SETDB1-1:1	chr1
CUST_7763.PI437845250111	-0.26	Down	0.01	MIR143HG	chr5
CUST_7598.PI437859739	-0.27	Down	0.00	lnc-VRK3-1	chr19
CUST_2130.PI437944915	-0.29	Down	0.00	lnc-DPH2-1	chr1
CUST_10938.PI437845420	-0.29	Down	0.01	lnc-RP11-105C20.2.1-11	chr16
CUST_2096.PI437845420	-0.32	Down	0.01	lnc-PTTG2-3	chr4
A_22.P00013297	-0.35	Down	0.00	lnc-RP11-1105G2.3.1-2:1	chr12
CUST_2402.PI437845420	-0.36	Down	0.01	lnc-HELQ-1	chr4
CUST_3265.PI437859739	-0.40	Down	0.00	lnc-RP11-80A15.1.1-2	chr14
CUST_9229.PI437859739	-0.58	Down	0.00	lnc-ARL6IP6-4	chr2
CUST_1809.PI437845420	-0.66	Down	0.00	lnc-DGKQ-1	chr4




Figure 2. lncRNAs were differentially expressed in exosomes of NSCLC patients and control groups

(A) Hierarchical clustering heatmaps showing lncRNA expression profiles ($P < 0.05$). (B) Volcano plots showing all detected lncRNAs in urinary exosomes from NSCLC patients ($n=3$) and control groups ($n=3$).




Figure 3. QT-PCR verification of differentially expressed lncRNAs

Relative expression levels of each selected lncRNAs were verified in NSCLC patients ($n=20$) and the control group ($n=20$) using QT-PCR. (A–C) Expression levels of lnc-FRAT1-5, lnc-SRY-11, and lnc-RNASE13-1 in NSCLC patients were significantly higher than those in healthy individuals (mean \pm SEM, *** $P<0.001$). (D–F) Expression levels of lnc-RP11-80A15.1.1-2, lnc-ARL6IP6-4, and lnc-DGKQ-1 were significantly down-regulated (mean \pm SEM, *** $P<0.001$).




Figure 4. Functional and network analyses of lncRNAs

(A) GO analysis for all lncRNA genes. Blue represents GO terms of biological processes, green represents the GO terms of cellular components, and orange represents GO terms of molecular functions. (B) GO enrichment histogram for differentially expressed lncRNA genes. (C) KEGG analysis based on lncRNA-target genes. (D) Construction of lncRNA-mRNA co-expression interaction network. A total of 98 lncRNAs and mRNAs were retained. Approx. 27 lncRNAs-mRNAs pairs (Pearson correlation ≥ 0.7 and ≤ -0.7) were selected to construct the lncRNA-mRNA network. Red square nodes represent 19 down-regulated lncRNAs, and purple triangle nodes represent mRNAs. Blue nodes represent regulation of mRNA. Green nodes represent the Pearson correlation coefficient.

and mRNAs were retained. Approximately 27 lncRNAs-mRNAs pairs (Pearson correlation ≥ 0.7 and ≤ -0.7) were selected to construct the lncRNA-mRNA network. The red square nodes in Figure 4D represent 19 down-regulated lncRNAs, while purple triangle nodes represent mRNAs, blue nodes represent the regulation of mRNA, and the green nodes represent the Pearson correlation coefficient.

Discussion

The morbidity and mortality of lung cancer exhibits a significant rising trend worldwide [3], such that lung cancer has become a significant hazard to human health and survival. Therefore, the survival rate of lung cancer patients heavily depends on improving early diagnosis and timely, appropriate treatment [2].

As excellent biological material, urine samples can be acquired in large volumes and in an entirely noninvasive manner [31,32]. Urinary exosomes are a novel reservoir for biomarker discovery and possible mediators of inter-cellular signaling containing proteins, miRNAs, and lncRNAs secreted by various types of healthy or tumor cells in numerous biological functions [33]. Exosomes collectively convey a specific message for neighboring or distant cells [34]. They can also serve as carriers of bioactive molecules to promote tumorigenesis and tumor metastasis [35].

As mentioned in the literature review, lncRNA is a class of noncoding RNAs of >200-nt length that does not encode proteins. lncRNAs are known to be able to regulate gene expression through diverse mechanisms [36]. Abundant evidence indicates that alterations in the expression profile of lncRNAs are associated with cancer tumorigenesis, invasion, differentiation, and metastasis, and may therefore serve as early disease indicators [37,38]. Available data indicate that numerous lncRNA levels are aberrant in NSCLC, and these lncRNAs play crucial roles in regulating NSCLC-associated pathways. Furthermore, they play very important roles in the critical biological process of NSCLC, such as tumor growth, metastasis, and angiogenesis [39,40].

Recently, some definite lncRNAs were discovered in exosomes secreted from lung cancer cells. Tang et al. reported that lncRNA *AFAP1-AS1* overexpression significantly promoted NSCLC cell proliferation, migration, and invasion, while inhibiting apoptosis in NSCLC [41]. Furthermore, the binding of *AFAP1-AS1* to IRF7 leads to the activation of the RIG-I like receptor signaling pathway and BclAS12, which may result in NSCLC proliferation and progression. These findings provide insight into a novel therapeutic target for NSCLC.

The present study reveals hundreds of lncRNAs and miRNAs. A total of 640 differentially expressed lncRNAs in exosomes secreted from the urine of the NSCLC patients were screened in comparison with those of healthy controls. Among them, 70 lncRNAs were significantly up-regulated, while 570 lncRNAs were significantly down-regulated. According to the QT-PCR results, lnc-FRAT1-5, lnc-SRY-11, and lnc-RNASE13-1 were up-regulated; lnc-RP11-80A15.1.1-2, lnc-ARL6IP6-4, and lnc-DGKQ-1 were down-regulated.

lncRNAs could interact with mRNAs to modulate the biological characteristics of NSCLC [42]. We predicted the potential target genes and constructed the co-expression network to elucidate the underlying molecular mechanisms of lncRNA function, which indicates that several lncRNAs may be involved in the pathogenesis of NSCLC. The results demonstrate actual differences in lncRNA expression of urinary exosomes between NSCLC patients and healthy controls.

The GO-enriched cluster analysis in the present study shows that in the cellular component class, the putative target genes are mostly related to the integral membrane, nucleus, and cytoplasm. In the biological process class, the putative target genes were mainly associated with transcription, small molecule metabolic process, and protein phosphorylation. In the molecular function class, the putative target genes were mostly related to the binding of protein, metal ions, and ATP.

The KEGG pathway analysis in the present study reveals that these target genes are significantly enriched in 20 pathways. The KEGG pathways were mostly enriched in the PI3K-AKT, FOXO, and p53 signaling pathways, as well as fatty acid biosynthesis. The differentially expressed lncRNAs in our study may regulate these pathways, which are associated with tumor cell proliferation, tumor cell apoptosis, and the cell cycle as part of their involvement in the pathogenesis of NSCLC.

Numerous studies showed that the PI3K/AKT/mTOR signaling pathway activates upstream receptors (EGFR and PDGF) and is mutated in a variety of cancers, including breast cancer, gastric cancer, and NSCLC [43–45]. The PI3K/Akt and p53 signaling pathways play a pivotal role in the development of NSCLC, regulating cell survival, proliferation, anti-apoptosis, and angiogenesis [46,47]. Dysregulation of the PI3K/AKT pathway has been reported to frequently occur in NSCLC [48]. Furthermore, the FOXO signaling pathway is closely associated with the PI3K/Akt signaling pathway.

Although we obtained positive results, it is necessary to further clarify the specific role of these lncRNAs in NSCLC. Furthermore, in future studies, we will explore the biological functions, mechanism of action, and signaling pathways of the differential expressed urinary exosome lncRNAs *in vitro*. In particular, we will focus on whether they are associated with the PI3K/AKT, FOXO, and p53 signaling pathways, fatty acid biosynthesis, and the p53 signaling pathway.

A shortcoming of our study is that we did not carry out a validation process. Further studies must be performed to reveal the role and regulatory mechanisms underlying the lncRNAs–mRNA network, and to determine whether the

expression level of these lncRNAs has already been altered at the very early stages of NSCLC. Furthermore, whether the expression level of these lncRNAs is changed before and after treatment remains a topic for future discussion.

In summary, lnc-FRAT1-5, lnc-SRY-11, lnc-RNASE13-1, lnc-RP11-80A15.1.1-2, lnc-ARL6IP6-4, and lnc-DGKQ-1 may be important regulators of NSCLC. Moreover, the present results suggest that these lncRNAs may regulate the PI3K/Akt, FOXO, or p53 signaling pathways. It was also demonstrated that these six lncRNAs may serve as potential markers of NSCLC metastasis.

Data Availability

The data included in the current study are available from the Refseq (<https://www.ncbi.nlm.nih.gov/refseq/>), Ensembl (<http://www.ensembl.org/>), UCSC (<https://genome.ucsc.edu/>), GENCODE (<https://www.genencodegenes.org/>), NONCODE (<http://www.noncode.org/>), and LNCipedia (<http://www.lncipedia.org/>) databases.

Competing Interests

The authors declare that there are no competing interests associated with the manuscript.

Funding

This work was supported by the Natural Science Foundation of Zhejiang Province [grant number LY19H160023]; and the Zhejiang Province Public Welfare Technology Application Research Project [grant number 2017C33022].

CRediT Author Contribution

Quan Lin: Data curation, Writing—original draft. **Danli Xie:** Writing—review & editing. **Liangliang Pan:** Methodology. **Yongliang Lou:** Project administration. **Mengru Shi:** Methodology, Project administration, Writing—review & editing.

Acknowledgements

We thank the the Department of Respiratory Medicine of the First Affiliated Hospital of Wenzhou Medical University for providing clinical samples in the present study.

Abbreviations

GO, gene ontology; HRP, horse radish peroxidase; KEGG, Kyoto Encyclopedia of Genes and Genomes; lncRNA, long noncoding RNA; NSCLC, non-small cell lung cancer; NTA, nanoparticle tracking analysis; QT-PCR, quantitative real-time PCR.

References

- Osmani, L., Askin, F., Gabrielson, E. and Li, K.Q. (2018) Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): moving from targeted therapy to immunotherapy. *Semin. Cancer Biol.* **52**, 103–109, <https://doi.org/10.1016/j.semcancer.2017.11.019>
- Siegel, R.L., Miller, K.D. and Jemal, A. (2020) Cancer statistics, 2020. *CA Cancer J. Clin.* **70**, 7–30, <https://doi.org/10.3322/caac.21590>
- Hind, R., Ehab, E.B., Antoine, F., Samah, N. and Imad, T. (2017) Immune-based therapies for non-small cell lung cancer. *Anticancer Res.* **37**, 377–387
- Bin, L., Fengmin, Z. and Hong, L. (2020) miR-1225-5p inhibits non-small cell lung cancer cell proliferation, migration and invasion, and may be a prognostic biomarker. *Exp. Ther. Med.* **20**, 172
- Fahad, M.A., Ahmed, A. and Mervat, S.M. (2019) Raloxifene-encapsulated hyaluronic acid-decorated chitosan nanoparticles selectively. *Bioorg. Med. Chem.* **27**, 1629–1638
- Qing, G., Tao, F., Boyou, Z., Wei, W. and Yao, X. (2014) Five microRNAs in plasma as novel biomarkers for screening of early-stage non-small. *Respir. Res.* **15**, 149
- Harding, C., Heuser, J. and Stahl, P. (1983) Receptor-mediated endocytosis of transferrin and recycling of the transferrin receptor in rat reticulocytes. *J. Cell Biol.* **97**, 329–339, <https://doi.org/10.1083/jcb.97.2.329>
- Chris, H. and Kevin, V.M. (2016) Form and function of exosome-associated long non-coding RNAs in cancer. *Curr. Top. Microbiol. Immunol.* **394**, 41–56
- Yamashita, T., Kamada, H., Kanasaki, S., Maeda, Y., Nagano, K. et al. (2013) Epidermal growth factor receptor localized to exosome membranes as a possible. *Pharmazie* **68**, 969–973
- Dong-Xue, G., Yi-Bei, W., Ming-Yang, H., Zi-Yang, C., Xiao-Xue, Q. et al. (2020) Lung cancer cells-controlled Dkk-1 production in brain metastatic cascade drive microglia to acquire a pro-tumorigenic phenotype. *Front. Cell. Dev. Biol.* **8**, 591405
- Igor, U. (2016) Evolution to the rescue: using comparative genomics to understand long non-coding. *Nat. Rev. Genet.* **17**, 601–614
- Mohammad, A.I., Shweta, A., Gopinath, P., George, A.C. and Mansoor, A.S. (2019) MicroRNA in lung cancer: role, mechanisms, pathways and therapeutic relevance. *Mol. Aspects Med.* **70**, 3–20

- 13 Liangyuan, C., Pengju, C., Qiumei, W., Yiqing, G., Yang, Y. et al. (2019) Overexpression of LncRNA-UCA1 correlates with lung adenocarcinoma progression and poor prognosis. *Clin. Lab.* **65**, <https://doi.org/10.7754/Clin.Lab.2018.180739>
- 14 Weijun, W., Yongying, H., Ke, W., Yue, C., Xia, P. et al. (2019) The LXR-623-induced long non-coding RNA LINC01125 suppresses the proliferation of breast cancer cells via PTEN/AKT/p53 signaling pathway. *Cell Death Dis.* **10**, 248
- 15 Chao, L., Yu, C., Long-Fei, L., Wen-Biao, R., Qia-Qia, L. et al. (2017) High expression of long noncoding RNA MALAT1 indicates a poor prognosis and promotes clinical progression and metastasis in bladder cancer. *Clin. Genitourin Cancer.* **15**, 570–576
- 16 Xi, W., Zhe, C., Lingling, D., Tianci, J., Pengfei, L. et al. (2021) LncRNA PVT1 facilitates proliferation, migration and invasion of NSCLC Cells via miR-551b/FGFR1 axis. *Oncotargets Ther.* **14**, 3555–3565
- 17 Alexandra, K., Szófia, B.N., Orsolya, G., István, C., András, B. et al. (2019) Genome-wide expression profiling in colorectal cancer focusing on lncRNAs in the adenoma-carcinoma transition. *BMC Cancer* **19**, 1059
- 18 Tang, Y., Jin-Ling, D., Cen, Y., Peng, L. and Qingshan, G. (2020) The lncRNAs RP1-261G23.7, RP11-69E11.4 and SATB2-AS1 are a novel clinical signature for predicting recurrent osteosarcoma. *Biosci. Rep.* **40**, BSR20191251
- 19 Yang, Y., Lei, C., Jin, G., Hanshuo, Z., Jiawei, Y. et al. (2017) Recurrently deregulated lncRNAs in hepatocellular carcinoma. *Nat. Commun.* **8**, 14421, <https://doi.org/10.1038/ncomms14421>
- 20 Farbod, E., Mohammad, T., Mir, D.O., Mohammad, B.S., Shahram, A.J. et al. (2019) Expression of long non-coding RNAs (lncRNAs) has been dysregulated in non-small cell lung cancer tissues. *BMC Cancer* **19**, 222
- 21 Lihuan, Z., Dongsheng, Z., Tianxing, G., Wenshu, C., Yun, D. et al. (2021) LncRNA GAS5 inhibits Invasion and Migration of Lung Cancer through influencing EMT process. *J. Cancer* **12**, 3291–3298
- 22 Shu-Hui, X., Gong-Xiang, L. and Lingli, Q. (2019) Long non-coding RNA BX357664 inhibits cell proliferation and metastasis in human lung cancer. *Oncol. Lett.* **17**, 2607–2614
- 23 Bing, H., Ramón, M.M., Nuria, V., Yangyi, H., Jordi, C. et al. (2021) Monitoring HOTTIP levels on extracellular vesicles for predicting recurrence in surgical non-small cell lung cancer patients. *Transl. Oncol.* **14**, 101144
- 24 Rui, Z., Yuhong, X., Zhixin, W., Jie, Z., Yafei, C. et al. (2017) Serum long non coding RNA MALAT-1 protected by exosomes is up-regulated and promotes cell proliferation and migration in non-small cell lung cancer. *Biochem. Biophys. Res. Commun.* **490**, 406–414
- 25 Lizhen, D., Guangming, L., Yongmei, L. and Ze, Z. (2019) Upregulation of long noncoding RNA GAS5 inhibits lung cancer cell proliferation and metastasis via miR-205/PTEN Axis. *Med. Sci. Monit.* **25**, 2311–2319
- 26 Mahul, B.A., Frederick, L.G., Stephen, B.E., Carolyn, C.C., Jeffrey, E.G. et al. (2017) The Eighth Edition AJCC Cancer Staging Manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. *CA Cancer J. Clin.* **67**, 93–99
- 27 Alvarez, M.L., Mahdiah, K., Rupesh, K.R. and Johanna, K.D. (2012) Comparison of protein, microRNA, and mRNA yields using different methods of urinary exosome isolation for the discovery of kidney disease biomarkers. *Kidney Int.* **82**, 1024–1032
- 28 Bow, J.T., David, W.G., Rommel, A.M., Hong, J., Suresh, M. et al. (2012) Comparison of ultracentrifugation, density gradient separation, and immunoaffinity capture methods for isolating human colon cancer cell line LIM1863-derived exosomes. *Methods* **56**, 293–304
- 29 Rebecca, A.D., Christopher, G., Alexandra, S.B., Dionne, S.T., David, J.P.F. et al. (2011) Sizing and phenotyping of cellular vesicles using Nanoparticle Tracking Analysis. *Nanomedicine* **7**, 780–788
- 30 Willis, G.R., Connolly, K., Ladell, K., Davies, T.S., Guschina, I.A. et al. (2014) Young women with polycystic ovary syndrome have raised levels of circulating annexin V-positive platelet microparticles. *Hum. Reprod.* **29**, 2756–2763, <https://doi.org/10.1093/humrep/deu281>
- 31 James, W.D., Jonathan, M.S. and Matthew, A.B. (2013) Urinary exosomes: a reservoir for biomarker discovery and potential mediators of intrarenal signalling. *Proteomics* **13**, 1572–1580
- 32 Zhou, H., Yuen, P.S.T., Pisitkun, T., Gonzales, P.A., Yasuda, H. et al. (2006) Collection, storage, preservation, and normalization of human urinary exosomes for biomarker discovery. *Kidney Int.* **69**, 1471–1476, <https://doi.org/10.1038/sj.ki.5000273>
- 33 Emanuele, F., Andrea, W., Fabrizio, B., Rossana, R., Antonella, D.P. et al. (2019) Urinary proteomics profiles are useful for detection of cancer biomarkers and changes induced by therapeutic procedures. *Molecules* **24**, 794
- 34 Ganesh, P., Nasser, A.D., Nilufar, M., Carsten, A.W., Ion, A.B. et al. (2018) Changes in V-ATPase subunits of human urinary exosomes reflect the renal response to acute acid/alkali loading and the defects in distal renal tubular acidosis. *Kidney Int.* **93**, 871–880
- 35 Ahmed, A., Hiroko, S., Ragab, E.S., Saki, T. and Masahiro, I. (2014) Urinary excretion pattern of exosomal aquaporin-2 in rats that received gentamicin. *Am. J. Physiol. Renal Physiol.* **307**, F1227–37
- 36 Arunoday, B., Milad, S. and Subhrangsu, S.M. (2017) Long noncoding RNA and cancer: a new paradigm. *Cancer Res.* **77**, 3965–3981
- 37 Maite, H., Mitchell, G., David, F., Manuel, G., Magdalena, J.K., Daniela, K.-B. et al. (2010) A large intergenic noncoding RNA induced by p53 mediates global gene repression in the p53 response. *Cell* **142**, 409–419
- 38 Toshimichi, Y., Naoto, I., Katsutoshi, I., Kenzui, T., Takeshi, K. et al. (2020) Systematic analysis of targets of pumilio-mediated mRNA decay reveals that PUM1 repression by DNA damage activates translesion synthesis. *Cell Rep.* **31**, 107542
- 39 Jing, F., Cheng-Cao, S. and Cheng, G. (2016) Long noncoding RNA XIST acts as an oncogene in non-small cell lung cancer by epigenetically repressing KLF2 expression. *Biochem. Biophys. Res. Commun.* **478**, 811–817
- 40 Jie, L., Yingjie, L., Bin, W., Yongfu, M. and Ping, C. (2018) LncRNA-PCAT-1 promotes non-small cell lung cancer progression by regulating miR-149-5p/LRIG2 axis. *J. Cell. Biochem.* **120**, 7725–7733, <https://doi.org/10.1002/jcb.28046>
- 41 Xiao-Di, T., Duo-Duo, Z., Linpei, J., Wei, J. and Yu-Shuang, Z. (2018) LncRNA AFAP1-AS1 promotes migration and invasion of non-small cell lung cancer via up-regulating IRF7 and the RIG-I-like receptor signaling pathway. *Cell. Physiol. Biochem.* **50**, 179–195
- 42 Maria, D.P. and Artemis, G.H. (2016) Analyzing miRNA-lncRNA interactions. *Methods Mol. Biol.* **1402**, 271–286
- 43 Kongliang, K. and Tingting, L. (2017) MicroRNA-10a suppresses breast cancer progression via PI3K/Akt/mTOR pathway. *Oncol. Lett.* **14**, 5994–6000

- 44 Jing, K., Peng, M., Jinpeng, C., Jun, Q. and Haixin, Q. (2018) LGR6 promotes the progression of gastric cancer through PI3K/AKT/mTOR pathway. *Oncotargets Ther.* **11**, 3025–3033
- 45 Xiaozhen, L., Tao, J., Li, X., Chao, Z., Jiayu, L. et al. (2020) Exosomes transmit T790M mutation-induced resistance in EGFR-mutant NSCLC by activating PI3K/AKT signalling pathway. *J. Cell. Mol. Med.* **24**, 1529–1540
- 46 Hsin-Yi, C., Chi-Ming, C., Szu-Peng, Y., De-Shien, J., Leang-Shin, W. et al. (2020) Effects of hyperinsulinemia on acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor via the PI3K/AKT pathway in non-small cell lung cancer cells in vitro. *Oncol. Lett.* **20**, 206
- 47 Aimei, Z., Xingli, L., Zongjiong, M., Junke, Z., Zhuohuan, L. et al. (2019) LINC00472 acts as a tumor suppressor in NSCLC through KLLN-mediated p53-signaling pathway via microRNA-149-3p and microRNA-4270. *Mol. Ther. Nucleic Acids* **17**, 563–577
- 48 Yoh, D., Shioto, S., Maiko, K., Hirochika, M., Hiroyoshi, T. et al. (2011) Paradigm of kinase-driven pathway downstream of epidermal growth factor receptor/Akt in human lung carcinomas. *Hum. Pathol.* **42**, 214–226




Figure S1. Western blot results of CD63, CD9, and Tsg101. Full uncropped and unedited versions of the western blots. Lane 1: protein ladder, Lane 2: NSCLC patient sample, Lane 3: healthy control sample.




Figure S2. Melting Curve of Inc-FRAT1-5. There is no impurity peak in the melting curve.

Table S1. Clinical characteristics of NSCLC patients and healthy controls of Figure 2.

Study groups	Gender	Age	Pathological type	Clinical stage
NSCLC patients	Male	68	Squamouscarcinoma	I+II stage
NSCLC patients	Male	61	Adenocarcinoma	III+IV stage
NSCLC patients	Female	65	Adenocarcinoma	I+II stage
healthy controls	Male	52		
healthy controls	Male	59		
healthy controls	Female	61		

Table S2. 100 Differential expression lncRNAs of urinary exosomes in NSCLC patients and controls.

ProbeName	log2FoldChange	regulation	pval	GeneName	Chr
CUST_3264_PI437859739	-0.08	down	0.00	lnc-SDR39U1-1	chr14
A_33_P3329462	-0.12	down	0.00	DLEU1 antisense RNA 1	chr13
CUST_4353_PI438111429	-0.18	down	0.00	PAOX	chr10
CUST_2784_PI437845420	-0.22	down	0.00	lnc-TMEM184C-5	chr4
CUST_6019_PI437845250111	-0.16	down	0.00	LINC00969	chr3
CUST_2130_PI437944915	-0.29	down	0.00	lnc-DPH2-1	chr1
CUST_18526_PI437845250111	-0.18	down	0.00	CTD-2528A14.1	chr19
A_21_P0008815	-0.08	down	0.00	lnc-C15orf2-1:1	chr15
A_22_P00013297	-0.35	down	0.00	lnc-RP11-1105G2.3.1-2:1	chr12
CUST_22164_PI437845420	-0.13	down	0.00		chr10
CUST_13585_PI437845420	0.64	up	0.00	lnc-FRAT1-5	chr10
CUST_2587_PI437859739	-0.09	down	0.00	lnc-TRPC4-2	chr13
A_22_P00007505	-0.10	down	0.00	lnc-GYPA-1:1	chr4
A_21_P0010215	-0.07	down	0.00	uncharacterized LOC101928576	chr21
A_21_P0011416	-0.08	down	0.00		chr16
CUST_16654_PI437845424	1.01	up	0.00		chr5
CUST_10328_PI437845424	-0.10	down	0.00		chr2
A_33_P3343820	-0.07	down	0.00	long intergenic non-protein coding RNA 632	chrX
CUST_9192_PI437845420	0.20	up	0.00	lnc-GARNL3-2	chr9
CUST_1452_PI437859739	-0.03	down	0.00	lnc-HDAC7-1	chr12
CUST_596_PI437845424	-0.04	down	0.00		chr11
CUST_2235_PI437845424	-0.05	down	0.00		chr12
A_33_P3386770	-0.24	down	0.00	lnc-MAPK15-3:3	chr8
CUST_13340_PI437845420	0.13	up	0.00	lnc-KCNMB2-11	chr3
CUST_7598_PI437859739	-0.27	down	0.00	lnc-VRK3-1	chr19
CUST_6877_PI437859739	-0.07	down	0.00	lnc-ELAVL1-1	chr19
CUST_21277_PI437845420	-0.25	down	0.00		chr1
CUST_1809_PI437845420	-0.66	down	0.00	lnc-DGKQ-1	chr4
CUST_9229_PI437859739	-0.58	down	0.00	lnc-ARL6IP6-4	chr2
CUST_1162_PI437956274	-0.25	down	0.00	TMPRSS4	chr11
CUST_3265_PI437859739	-0.40	down	0.00	lnc-RP11-80A15.1.1-2	chr14
CUST_8505_PI437845420	-0.25	down	0.00	lnc-C9ORF123-7	chr9
CUST_625_PI437944915	-0.05	down	0.00	PRR36	chr19
CUST_4271_PI437845420	0.12	up	0.00	lnc-ITK-2	chr5
A_19_P00317168	-0.15	down	0.00		chr10
CUST_6705_PI437845420	-0.11	down	0.00	lnc-GNGT1-2	chr7
CUST_7409_PI437859739	-0.23	down	0.00	lnc-PRR19-1	chr19
CUST_5480_PI438111429	-0.14	down	0.00	lnc-RP11-664I21.6.1-1	chr11

CUST_2899_PI437944915	-0.07	down	0.01	lnc-LYSMD1-3	chr1
CUST_10938_PI437845420	-0.29	down	0.01	lnc-RP11-105C20.2.1-11	chr16
CUST_19112_PI437845420	-0.08	down	0.01	CAHM	chr6
CUST_8525_PI437845250111	-0.16	down	0.01	BVES-AS1	chr6
CUST_20092_PI437845250111	0.43	up	0.01	CECR5-AS1	chr22
CUST_14594_PI437845420	-0.20	down	0.01	lnc-TMCO5A-3	chr15
CUST_22841_PI437845250111	-0.01	down	0.01	linc-FAM153A-2	chr5
A_22_P00025006	-0.17	down	0.01	lnc-SHISA9-4:1	chr16
A_22_P00010823	-0.23	down	0.01	long intergenic non-protein coding RNA 1470	chr5
CUST_17296_PI437845250111	-0.02	down	0.01	RP11-156P1.3	chr17
CUST_19478_PI437845424	-0.25	down	0.01		chr7
CUST_17215_PI437845424	-0.44	down	0.01		chr6
A_21_P0000741	-0.10	down	0.01	ADAMTS9 antisense RNA 2	chr3
CUST_22957_PI437845424	-0.18	down	0.01		chr9
CUST_2402_PI437845420	-0.36	down	0.01	lnc-HELQ-1	chr4
A_21_P0011909	-0.08	down	0.01		chr2
CUST_7029_PI437859739	0.17	up	0.01	lnc-EPHX3-3	chr19
A_19_P00807507	-0.05	down	0.01	lnc-MRGPRF-4:2	chr11
CUST_1939_PI437845424	-0.19	down	0.01		chr12
A_21_P0005953	-0.13	down	0.01	lnc-KHDRBS3-5:4	chr8
CUST_5206_PI437845420	-0.14	down	0.01	lnc-YIPF3-2	chr6
CUST_17529_PI437845420	-0.12	down	0.01	lnc-TEC-2	chr4
A_21_P0012140	-0.09	down	0.01	uncharacterized LOC101926935	chr20
CUST_10296_PI437845420	0.59	up	0.01	lnc-SRY-11	chrY
CUST_16886_PI437845250111	-0.23	down	0.01	AL353997.3	chr17
CUST_20748_PI437845424	-0.24	down	0.01		chr8
CUST_8565_PI437845424	-0.57	down	0.01		chr2
CUST_10704_PI437845424	-0.30	down	0.01		chr20
CUST_11506_PI437845424	-0.09	down	0.01		chr21
CUST_6659_PI437859739	-0.25	down	0.01	lnc-POLR2E-2	chr19
CUST_6315_PI437845424	-0.17	down	0.01		chr17
CUST_12960_PI437845250111	-0.09	down	0.01	RP11-831A10.2	chr11
CUST_14229_PI437845250111	-0.08	down	0.01	RP11-394A14.4	chr13
CUST_19156_PI437845424	-0.18	down	0.01		chr7
CUST_9289_PI437859739	-0.24	down	0.01	lnc-PSMD14-4	chr2
CUST_14873_PI437845424	-0.14	down	0.01		chr4
CUST_6692_PI437845420	0.20	up	0.01	lnc-ANKIB1-2	chr7
CUST_7763_PI437845250111	-0.26	down	0.01	MIR143HG	chr5
A_22_P00016230	-0.07	down	0.01	CATIP antisense RNA 1	chr2
CUST_12091_PI437845420	-0.20	down	0.01	lnc-ARNTL-4	chr11

A_33_P3523501	0.09	up	0.01		chr19
CUST_14805_PI437845424	-0.30	down	0.01		chr4
A_22_P00019021	0.09	up	0.01	lnc-SETDB1-1:1	chr1
CUST_22430_PI437845420	0.27	up	0.01		chr10
CUST_2096_PI437845420	-0.32	down	0.01	lnc-PTTG2-3	chr4
CUST_7738_PI437859739	-0.23	down	0.01	lnc-FAM71E2-1	chr19
A_21_P0005072	-0.23	down	0.01	lnc-NOX3-2:1	chr6
A_21_P0013669	-0.11	down	0.01	uncharacterized LOC101927993	
A_21_P0013002	-0.47	down	0.01		chr5
CUST_1895_PI437845420	-0.06	down	0.01	lnc-CYTL1-2	chr4
CUST_3081_PI437859739	0.48	up	0.01	lnc-RNASE13-1	chr14
CUST_12451_PI437845420	-0.75	down	0.01	lnc-FAM69C-4	chr18
CUST_7974_PI437845424	-0.08	down	0.01		chr19
CUST_8082_PI437845250111	-0.12	down	0.01	ELOVL2-AS1	chr6
CUST_2030_PI437944915	-0.06	down	0.01	lnc-SNIP1-1	chr1
A_21_P0009794	-0.25	down	0.01	lnc-VN1R2-1:2	chr19
CUST_14622_PI437845424	-0.09	down	0.01		
A_21_P0006966	-0.27	down	0.01	uncharacterized LOC101928322	chr10
A_22_P00003087	-0.12	down	0.01	lnc-C8orf74-1:1	chr8
CUST_449_PI437944915	-0.12	down	0.01	PNMT	chr17
CUST_7866_PI437845250111	-0.14	down	0.01	CTB-174D11.1	chr5